Unveiling demographic and socioeconomic patterns in hidradenocarcinoma: A retrospective National Cancer Database study.

e21580 Background: Hidradenocarcinoma is a rare and malignant tumor arising from the eccrine or apocrine sweat glands. Hidradenocarcinoma has the potential to mimic benign lesions, which can lead to misdiagnosis. Mohs micrographic surgery (MMS) for hidradenocarcinoma has demonstrated excellent outcomes, with no observed recurrences, metastases, or disease-related deaths. Due to this malignancy's rarity and aggressive course, analyzing diagnostic patterns can offer valuable insights into its epidemiology. This study utilized the National Cancer Database (NCDB) to investigate demographic factors among patients diagnosed with hidradenocarcinoma. Methods: A retrospective National Cancer Database (NCDB) from 2004 to 2020 analyzed patients who had a histologically confirmed diagnosis of Hidradenocarcinoma (ICD-O-3 8402). Descriptive statistics analyzed demographic factors, including age, sex, race, Hispanic status, educational attainment, insurance status, facility type, distance from the facility, and Charlson-Deyo score. Regression analysis was applied to interpret incidence trends. Results: A total of 699 patients were identified in the database with a confirmed diagnosis of Hidradenocarcinoma, with a moderate upward trend in incidence from 2004 to 2020 (R^2 = 0.60). Approximately males and females were affected equally (53% and 47%, respectively). Most of the patients were White (81%) and non-Hispanic (89%). The median age at diagnosis was 62 years (SD = 16.66; range, 13–90). Most patients (79% ) had a Charlson-Deyo comorbidity score of 0. The primary sites were predominantly the skin of the trunk (26%) and the skin of the lower limb and hip (23%) with a median tumor size of 22 mm (SD = 26.20; range, 1.00–200.00). The majority of patients (90%) underwent surgery, 17% received radiotherapy, and 2% received chemotherapy. Forty-five percent of patients utilized private insurance or managed care, while 42% utilized Medicare. Approximately half of the patient population (46%) received treatment at an academic or research program, rather than a comprehensive community cancer program (28%). The 10-year survival rate was 91.3%, and the mean survival was 150 months. Conclusions: To the best of our knowledge, this is the first NCDB analysis on Hidradenocarcinoma and addresses a significant knowledge gap. The majority of hidradenocarcinoma patients were White and non-Hispanic, with primary diagnoses predominantly involving the skin of the trunk and skin of the lower limb and hip. For the first time, the socioeconomic characteristics of Hidradenocarcinoma patients have been documented, such as the finding that patients are more likely to receive treatment at an academic or research program. Further research is needed to investigate how demographic and socioeconomic factors affect the diagnosis, treatment, and survival of patients with hidradenocarcinoma.